首页> 外文期刊>Alimentary pharmacology & therapeutics. >Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
【24h】

Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.

机译:结肠镜检查对照的个体内比较,以筛查相关的瘤形成:粪便免疫化学测试与基于愈创木脂的粪便潜血测试。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior. AIM: To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-controlled population. METHODS: We assessed sensitivity and specificity of both FIT (OC-sensor) and g-FOBT (Hemoccult-II) prior to patients' scheduled colonoscopies. RESULTS: Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive in 46 and FIT in 54 (74.2% vs. 87.1%, P = 0.02). Among 194 patients with advanced adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P < 0.001). Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II cancers) was 23.0% for g-FOBT and 40.5% for FIT (P < 0.001). Specificity of g-FOBT compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P < 0.001) and for advanced adenomas (97.4% vs. 94.2%, P < 0.001). CONCLUSIONS: Faecal immunochemical test is more sensitive for CRC and advanced adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared with FIT.
机译:背景:基于番石榴的粪便潜血测试(g-FOBTs)最常用于结直肠癌(CRC)筛查程序。粪便免疫化学测试(FIT)被认为是更好的。目的:比较g-FOBT和定量FIT在结肠镜检查控制人群中检测CRC和晚期腺瘤的性能。方法:我们在患者进行预定结肠镜检查之前评估了FIT(OC传感器)和g-FOBT(Hemoccult-II)的敏感性和特异性。结果:在1821名个体中检测到的62种浸润性癌症中,g-FOBT阳性46例,FIT阳性54例(74.2%对87.1%,P = 0.02)。在194例晚期腺瘤患者中,g-FOBT阳性35例,FIT阳性69例(18.0%对35.6%,P <0.001)。筛查相关肿瘤(197例晚期腺瘤和28个I或II期癌症)的敏感性,对g-FOBT为23.0%,对FIT为40.5%(P <0.001)。与FIT相比,g-FOBT检测癌症的特异性为95.7%vs. 91.0%,P <0.001)和晚期腺瘤的特异性(97.4%vs. 94.2%,P <0.001)。结论:粪便免疫化学检测对CRC和晚期腺瘤更敏感。 FIT对筛查相关肿瘤,早期癌症和晚期腺瘤的敏感性明显更高。与FIT相比,g-FOBT的特异性更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号